Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Pancreatic Cancer Treatment market size was estimated at USD 3.46 billion in 2021 and is expected to surpass around USD 10.2 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 9.4% during the forecast period 2022 to 2030.

Growth Factors:

The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel market growth. In addition, the growing geriatric population is expected to drive the growth of the pancreatic cancer treatment industry during the forecast period. Apart from lifestyle-dependent factors, a personal or family history of pancreatitis and BRCA2 mutation predisposes a person to pancreatic cancer.

A number of imaging techniques such as CT scan, MRI, and ultrasound are used for the diagnosis of the disease. Chemotherapy is the most common form of treatment provided by medical practitioners and oncologists. Currently, there are only four drugs approved by the U.S. FDA for the treatment of pancreatic cancer: ABRAXANE, (albumin-bound paclitaxel); Gemzar (gemcitabine); 5-FU (fluorouracil); and ONIVYDE (irinotecan liposome injection). Apart from these four drugs, FOLFIRINOX, a combination of three chemotherapy drugs (5-FU/leucovorin, irinotecan, and oxaliplatin) is commonly used in the treatment of metastatic pancreatic adenocarcinoma. Other emerging chemotherapies for advanced pancreatic cancer combined with agents already approved for use are being investigated in clinical trials.

In developing countries, governments are continuously investing a huge amount of funds in improving patient-centered care. The increasing geriatric population base, rising prevalence of pancreatic cancer cases, and rapid growth in foreign investments are expected to be witnessed over the forecast period in the developing nations of the Asia Pacific and the Middle East region.

Report Scope of the Pancreatic Cancer Treatment Market

Pancreatic Cancer Treatment Market Trends

Increasing investments in the healthcare sector, a steady rise in the geriatric population, and an increase in the number of cancer cases are projected to enhance market growth during the projection period. According to the International Diabetic Federation, in 2021, 537 million adults had diabetes and over 39.9% of adults worldwide were overweight. The risk of pancreatic cancer increases with rising incidences of diabetes and obesity, thus influencing the market. Furthermore, the rise in healthcare expenditure to aid infrastructure development, as well as initiatives undertaken by various government and private organizations, are projected to raise awareness about molecular biology, which in turn will propel market growth.

An increase in research & development activities will create new opportunities for the market. Furthermore, the growing frequency of drug launches and approvals benefits the market greatly. Growth and advancement in the development of new technologies and increased investments additionally provide beneficial opportunities for the market. For instance, the National cancer institute of the United States is currently researching the development of a blood test that could diagnose pancreatic cancer in its early stages. However, high costs related to the treatment and stringent government policies are restraints expected to slow down industry growth.

Affected Region Insights

The global pancreatic cancer treatment industry has been segmented into the type of affected region and application. The affected region segment is categorized into exocrine and endocrine. Most of the pancreatic cancers diagnosed in the world belong to an exocrine category, thus the segment currently dominates the market. The endocrine type of cancer, although less prevalent, is still awaiting effective treatment modalities.

The investment in R&D is significant in both types of cancers. However, the increasing prevalence and growing reach of novel techniques in the developing regions are the factors expected to drive the growth of the exocrine segment throughout the forecast period.

Type Insights

Based on type, the pancreatic cancer market is segmented into chemotherapy, targeted therapy, and others that mainly include surgery, radiation techniques, and other therapies. Targeted therapy dominated the market in 2021 and is expected to dominate throughout the forecast period.

The factors driving growth include the introduction of the novel biologic therapies and targeted drugs in order to minimize the adverse effects of the existing therapies, including chemotherapy. Demand for targeted drugs is expected to rise significantly during the forecast period.

Regional Insights

North America dominated the pancreatic cancer treatment industry with the largest revenue share in 2021. The dominance of this region is mainly attributed to the improved healthcare infrastructure, high adoption of pancreatic treatment procedures, and the presence of a large target population. In addition, an increasing incidence of pancreatic cancer is aggressively propelling the demand for treatment options.

On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. The presence of well-established hospitals and critical care centers as well as a large population suffering from pancreatic cancer would boost the growth of the market in the Asia Pacific region. Furthermore, with the growing number of pancreatic cancer cases in the Asia Pacific region, the diagnosis and treatment of pancreatic cancer in the region must adhere to the same regimen as followed in western countries.

Recent Developments

• In January 2022, for pancreatic cancer treatment, the U.S. Food and Drug Administration (FDA) gave orphan drug status to multitargeted T-cell therapy. This therapy has shown the potential to elicit sustained responses in individuals with advanced or metastatic pancreatic cancer when combined with chemotherapy as a first-line therapeutic option
• In February 2022, Eli Lilly and Company and UNICEF declared a collaboration aimed at improving healthcare facilities for around 10 million children and adolescents suffering from non-communicable diseases
• In July 2021, Novartis’ NIS793 monoclonal antibody received the Orphan Drug Designation (ODD) from the FDA, with regard to pancreatic cancer

Some of the prominent players in the Pancreatic Cancer Treatment Market include: Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Pfizer, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Pancreatic Cancer Treatment market

• By Affected region

• Exocrine
• Endocrine
• Type
• Chemotherapy
• Targeted Therapy
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Pancreatic Cancer Treatment Market Study:

• Growth of Pancreatic Cancer Treatment in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Pancreatic Cancer Treatment and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Pancreatic Cancer Treatment Consumption Analysis
•  Pancreatic Cancer Treatment Production Analysis
•  Pancreatic Cancer Treatment and Management